Abstract
Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem cell disorder that is characterized by florid bone marrow stromal reaction including collagen fibrosis, osteosclerosis, and angiogenesis. Almost all patients with MMM display increased bone marrow microvessel density (MVD) and the extent is among the highest in hematological malignancies. This particular information has encouraged the therapeutic use of anti-angiogenic drugs in MMM. In the current review, we summarize the general concepts regarding angiogenesis, assessment of angiogenesis in hematological malignancies and then the current literature on angiogenesis and anti-angiogenic therapy in MMM.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2373-2386 |
| Number of pages | 14 |
| Journal | Leukemia and Lymphoma |
| Volume | 45 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2004 |
Keywords
- Agnogenic myeloid metaplasia
- Angiogenesis
- Anti-antigenesis treatment
- MPD
- Myelofibrosis
- Myelofibrosis therapy
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research